Long Noncoding RNA XIST Promotes Resistance to Lenvatinib in Hepatocellular Carcinoma Cells via Epigenetic Inhibition of NOD2

Figure 1

Upregulation of lncXIST confers resistance to lenvatinib in HCC cells. (a) HepG2 and HepG2/R cells were treated with indicated doses of lenvatinib for 24 h, and cellular viabilities were measured. (b) HepG2 and HepG2/R cells were treated with or without lenvatinib for 24 h, and indicated proteins were measured by western blots. (c) HepG2 and HepG2/R cells were subjected to the RNA sequencing analysis. (d) Top significantly affected pathways in HepG2/R cells based on KEGG pathway enrichment analysis. (e) Levels of lncXIST were measured in various cell lines. (f) The IC50 values of various HCC cells under the treatment of lenvatinib. (g) HepG2/R cells were transfected with various siRNAs for 24 h, and levels of lncXIST were measured. (h) HepG2 cells were transfected with empty vector (pcDNA) or lncXIST expressing vector (pc-XIST) for 24 h, and the levels of lncXIST were measured. (i) After knockdown of lncXIST or overexpressing lncXIST, the IC50 values were measured in HepG2/R and HepG2 cells, respectively. (j) HepG2/R and HepG2 cells were transfected with siRNA against lncXIST or vector expressing lncXIST, then cells were treated with or without Lenvatinib (10 μM) for various time, and cellular viabilities were measured. The data was presented as . and .

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)